None listed
Conditions
Interventions
Methadone Type of group
Patients who have not previously received opioids: start with methadone 2.5 to 5mg every 8 hours orally, according to the patient age, weight and pain intensity.
Patients who have previously received morphine: For the change from morphine to methadone the 1 in 3 in 3 days method should be used: reducing 1 in 3 of the morphine dose every day and replacing it with methadone
Sponsors
DROGERIA MARFAN S.A.C.,
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient diagnosed with cancer confirmed by histology 2. Age between 18 and 70 years. 3. Presence of a pain lasting more than 30 days. 4. Pain secondary to cancer or its treatment. 5. Somatic, visceral, neuropathic or mixed pain 6. Intensity of pain of moderate, intense or very intense degree 7. Kamofsky equal to or greater than 60. 8. Patients who have used the 1st and 2nd therapeutic steps of the WHO require the use of a strong opioid. 9. Patients who accept and can sign an informed consent. 10. Patients who can read, write and do not have cognitive impairment. 11. Patients able to keep a diary during their participation in the study.
Exclusion criteria
Exclusion criteria: 1. Presence of a pain maintained by the sympathetic. The presence of a pain maintained by the sympathetic is suspected when there is a severe pain, burning-like, associated with allodynia (pain secondary to innocuous stimulation in normal skin), hyperpathy (presence of pain after a stimulus is finished), changes trophic skin and its annexes, hard edema and osteoporosis. 2. Vital functions (blood pressure, heart rate and respiratory rate unstable or abnormal. 3. Pregnant or lactating patient. 4. Presence of liver, kidney or respiratory failure, asthma, chronic obstructive pulmonary disease, intracranial hypertension or a history of paralytic ileus. 5. Allergy to morphine or other opioids. 6. Patients scheduled for surgery, chemotherapy, radiotherapy or hormonotherapy during the study period. 7. Patients who received chemotherapy or radiotherapy, or change in the hormonal regimen in the 14 days prior to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Efficacy will be measured according to the pain assessment scale (visual numerical color scale -EVNC) Tolerability is defined as absence of intense side effects attributed to methadone; nausea and / or vomiting not controllable with drugs and others The intensity of the pain according to the EVNC scale, which consists of a color bar that gradually changes from white to intense red, where white indicates absence of pain and corresponds to the number 0, and that increasingly reaches number 10, which corresponds to the intense red and indicates the presence of very severe pain Measure:Efficacy, tolerability and intensity Timepoints:From the 7th day to the 14th day ; Outcome name:Efficacy is measured according to the pain assessment scale (visual numerical color scale EVNC) Tolerability is defined as such in the absence of intense side effects attributed to methadone; nausea and / or vomiting not controllable with drugs and others The intensity of the pain according to the EVNC scale, which consists of a color bar that gradually changes from white to intense red, where white indicates absence of pain and corresponds to the number 0, and that increasingly reaches number 10, which corresponds to the intense red and indicates the presence of very severe pain Measure:Efficacy, tolerability and intensity Timepoints:Day 7 and Day 14 | — |
Countries
Peru
Outcome results
None listed